U.S. Markets closed

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.0000-0.1200 (-2.91%)
At close: 4:00PM EST

Virpax Pharmaceuticals, Inc.

1055 Westlakes Drive
Suite 300
Berwyn, PA 19312
United States
610 727 4597

Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony P. MackChairman & CEO375kN/A1962
Mr. Christopher M. Chipman CPA, CPACFO & Corp. Sec.72kN/A1972
Dr. Jeffrey A. GudinExec. VP, Chief Medical Officer & DirectorN/AN/A1966
Dr. Sheila A. Mathias J.D., M.B.A., Ph.D.Chief Scientific OfficerN/AN/AN/A
Shana PanzarellaChief of StaffN/AN/AN/A
Mr. Gerald W. BruceExec. VP of Commercial OperationsN/AN/A1957
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Corporate Governance

Virpax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.